Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A conversation with Milissa, chronic pain patient

Milissa is a college graduate with a bachelor degree in Economics and played D1 tennis before moving on to the professional circuit. Due to many orthopedic injuries, she had no choice but to retire and began her business career in banking shortly thereafter. She quickly realized the industry wasn’t for her and accepted an entry-level position at an Advertising Agency. She’s now a Vice President with an agency she’s been with for over 30-years. Her work has allowed her to film commercials within the US and abroad, including Rwanda, London and Banff, Canada, just to name a few incredible locations.

Milissa’s injuries from playing sports, particularly tennis, have been many – she’s had over 22 surgeries including 12 to her knees along with both shoulders, foot, wrists, etc. Her predominant injury is to her spine, which resulted in a 3-level spinal fusion in 2017.

#burdenofpain #chronicpain

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!